S1616- A Phase II Randomized Study Of Nivolumab (Nsc-748726) With Ipilimumab (Nsc-732442) Of Ipilimumab Alone In Advanced Melanoma Patients Refractory To An Anti-Pd1 Or Anti-Pd-L1 Agent
Posted Date: Mar 6, 2020
- Investigator: Rekha Chaudhary
- Specialties: Cancer, Oncology, Skin Cancer
- Type of Study: Drug
To compare progression free survival (PFS) of patients with advanced melanoma refractory to an anti-PD-1 or anti-PD-L1 agent, treated with combination therapy ipilimumab plus nivolumab versus ipilimumab alone
Criteria:
To Be Eligible: Pathologically Confirmed Melanoma That Is Either Stage Iv Or Unresectable Stage Iii, Progression On Prior Anti-Pd1 Treatment, No Systemic Therapy Within 21 Days, Zubrod Performance Status Of = 2, Active Or Uncontrolled Infection Or Illness
Keywords:
Melanoma, Skin Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com